# CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

> **NCT00004026** · PHASE2 · TERMINATED · sponsor: **CTI BioPharma** · enrollment: 80 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** CT-2584
- **DRUG:** chemotherapy

## Key facts

- **NCT ID:** NCT00004026
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1998-12
- **Primary completion:** 2005-01
- **Final completion:** 2005-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004026, "CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00004026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*